Recent Advances in Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE Gene Fusions

Authors

  • Yunguang Liu, MD, PhD
  • Bo Xu, MD, PhD
  • Frank Chen, MD, PhD

Keywords:

renal cell carcinoma, Xp11.2 translocations/TFE gene fusions, clinical presentation, cytogenetic profile, histopathology, prognosis and treatment

Abstract

Renal cell carcinoma associated with Xp11.2 translocations/TFE gene fusions (Xp11.2 RCC) has been classified as a distinct entity in the 2004 WHO classification of kidney tumors.  Over the past seven years, aided by increased awareness, positive nuclear staining for TFE3, unique cytogenetic features, and modern molecular technology, more cases have been recognized as Xp11.2 RCC.  This review summarizes the most recent advances in Xp11.2 RCC regarding to its clinical presentation, cytogenetic profile, histopathology, prognosis and treatment.

Downloads

Published

2012-01-31

How to Cite

Liu, MD, PhD, Y., Xu, MD, PhD, B., & Chen, MD, PhD, F. (2012). Recent Advances in Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE Gene Fusions. North American Journal of Medicine and Science, 5(1). Retrieved from https://najms.com/index.php/najms/article/view/288

Issue

Vol. 5 No. 1 (2012)

Section

Review